Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | CA7 | P43166 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.56 |
| ▸ | XDH | P47989 | 1/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10785661 | 0.91 | ESR1 (0.65) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL8204859 | 0.89 | NSD2 (0.71) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL30674458 | 0.89 | NSD2 (0.71) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL13286874 | 0.86 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3004439 | 0.83 | NSD2 (0.79) | SERPINE1XDHNSD2ESR1ESR2 | |
| SCHEMBL8756285 | 0.82 | CA12 (0.53) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL10784179 | 0.81 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3005074 | 0.81 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21681863 | 0.81 | ESR1 (0.56) | SERPINE1CA12CA1CA2CA7 | |
| SCHEMBL2761252 | 0.80 | CA1 (0.62) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527878-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-01-14 | — | — | US | disclosed |
| US-9120744-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120744-B2 | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-09-01 | — | — | US | disclosed |
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2010-06-03 | — | — | US | disclosed |
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137194-A1 | Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism | SERPINE1, PLAT, SERPINB1 | SERPINE1 1/4885CA12 4021/4885CA1 3712/4885 |
| US-20160009748-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM | SERPINE1, PLAT, SERPINB1 | SERPINE1 1/4885CA12 4021/4885CA1 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.